Maka Vinayak V, Rajanna Hithashree, Narasiyappah Anil Kumar, Chitrapur Rohith, Kilara Nalini
Department of Medical Oncology , M S Ramaiah Medical College , Bangalore , India.
Department of Ophthalmology , Vijayanagar Institute of Medical Sciences , Bellary , India.
Oxf Med Case Reports. 2014 Aug 5;2014(5):98-9. doi: 10.1093/omcr/omu038. eCollection 2014 Aug.
Advances in understanding of the mechanisms involved in oncogenesis have led to the development of targeted therapies such as epidermal growth factor receptor inhibitors (EGFRIs), targeting a variety of molecular structures and able to inhibit aberrantly activated oncogenic pathways. Their use made treatment more tolerable with significant reduction of systemic adverse effects. However, EGFRIs are associated with toxicities affecting the skin and adnexal structures that affect the majority of treated patients. Trichomegaly of eyelashes is a unique side-effect, seen in prolonged treatment with EGFRI. It is essential to be familiar with this adverse effect, its potential complications, long-term sequelae, and available effective treatment strategy in order to appropriately manage these patients.
对肿瘤发生机制认识的进展导致了靶向治疗的发展，如表皮生长因子受体抑制剂（EGFRIs），其作用于多种分子结构，能够抑制异常激活的致癌途径。它们的使用使治疗更易于耐受，全身不良反应显著减少。然而，EGFRIs与影响皮肤和附属器结构的毒性相关，这影响了大多数接受治疗的患者。睫毛粗长是一种独特的副作用，见于EGFRIs的长期治疗。熟悉这种不良反应、其潜在并发症、长期后遗症以及可用的有效治疗策略对于妥善管理这些患者至关重要。
